2,2-dimethyl-4H-benzo[d][1,3]dioxine-8-carbaldehyde | 1276668-15-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 2,2-dimethyl-4H-benzo[d][1,3]dioxine-8-carbaldehyde
• 英文别名: 2,2-dimethyl-4H-1,3-benzodioxine-8-carbaldehyde
• CAS: 1276668-15-5
• 化学式: C₁₁H₁₂O₃
• 分子量: 192.214
• InChiKey: ZTLYTPXHWPXRCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,2-dimethyl-4H-benzo[d][1,3]dioxine-8-carbaldehyde 在 sodium tetrahydroborate 、 magnesium sulfate 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 37.0h， 生成 2-trimethylsilylethyl N-[(5S)-5,6-bis[bis[(2-methylpropan-2-yl)oxy]phosphorylmethyl-[(2,2-dimethyl-4H-1,3-benzodioxin-8-yl)methyl]amino]hexyl]carbamate
  参考文献：
  名称：

  Contrast enhancement agents and method of use thereof

  摘要：

  提供了一种对比剂组合物和一种诊断成像方法。该组合物包括一种药用载体和一种金属配合物，其包括具有结构（XXX）的配体：其中R1、R2、R3、R7、R8、R′1、R′2、R′3、R7′和R8′从氢、受保护的C1-C3羟基烷基或C1-C3烷基中选择；R4、R′4从氢、羟基、受保护的羟基基团、受保护的C1-C3羟基烷基或C1-C3烷基中选择；n是0到4之间的整数；R5、R′5从氢、包含C1-C30脂肪基、C3-C30环脂基、C2-C30芳香基的保护基中选择；m是1到10之间的整数；R7和R′7中的至少一个是酸性基团或受保护的酸性基团；Y包括蛋白质或肽基团、粒子、胶束、脂质体、有机分子、寡聚体、聚合物或亲水基团。

  公开号：

  US09155804B2
• 作为产物：
  描述：

  3-bromosalicyl alcohol isopropylidene acetal 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 2.0h， 生成 2,2-dimethyl-4H-benzo[d][1,3]dioxine-8-carbaldehyde
  参考文献：
  名称：

  BIFUNCTIONAL CHELATING AGENTS

  摘要：

  提供了一种螯合剂、金属螯合物和对比剂，其中螯合剂包括结构（I）的化合物，其中R1、R2、R3、R8、R7、R′7、R′1、R′2、R′3和R8′从氢、受保护的C1-C3羟基烷基基团、C1-C3烷基基团中选择；R4和R′4从氢、羟基、受保护的羟基、受保护的C1-C3羟基烷基基团、C1-C3烷基基团中选择；n是0到4之间的整数；R5和R′5从氢、选自C1-C30脂肪基、C3-C30环脂肪基、C2-C30芳香基的保护基中选择；R9和R′9从氢或选自C1-C30脂肪基、C3-C30环脂肪基、C2-C30芳香基的保护基中选择；m是0到10之间的整数；并且R7和R′7中的至少一个是酸性基团或受保护的酸性基团。

  公开号：

  US20140088314A1

文献信息

• HYDROXYLATED CONTRAST ENHANCEMENT AGENTS AND IMAGING METHOD
  申请人：Grimmond Brian James

  公开号：US20110243858A1

  公开（公告）日：2011-10-06

  A method of diagnostic imaging is disclosed comprising administering a medical formulation to a subject, the formulation comprising a contrast enhancement agent having structure I and salts thereof wherein R 1 is independently at each occurrence a hydroxy group, a C 1 -C 3 hydroxyalkyl group, or a C 1 -C 3 alkyl group, and b is 0-4; R 2 -R 7 are independently at each occurrence hydrogen, a C 1 -C 3 hydroxyalkyl group, or a C 1 -C 3 alkyl group, with the proviso that at least one of R 1 -R 7 is a hydroxy group or a C 1 -C 3 hydroxyalkyl group; and wherein Q is one or more charge balancing counterions; and one or more pharmaceutically acceptable carriers and excipients. The subject is subjected to a diagnostic imaging technique such as magnetic resonance imaging. The technique may be used in a variety of diagnostic imaging regimes, such as imaging of circulatory systems, genitourinary systems, hepatobiliary systems, central nervous systems, tumors, and abscesses among others.

  揭示了一种诊断成像方法，包括向受试者注射医用配方，该配方包括具有结构I和其盐的对比增强剂，其中R1在每次出现时独立地是羟基、C1-C3羟基烷基或C1-C3烷基，b为0-4；R2-R7在每次出现时独立地是氢、C1-C3羟基烷基或C1-C3烷基，但至少其中之一是羟基或C1-C3羟基烷基；Q是一个或多个电荷平衡的对离子；以及一个或多个药用载体和赋形剂。受试者接受诊断成像技术，如磁共振成像。该技术可用于各种诊断成像方案，如循环系统、泌尿系统、肝胆系统、中枢神经系统、肿瘤和脓肿等的成像。
• CONTRAST ENHANCEMENT AGENTS AND METHOD OF USE THEREOF
  申请人：GENERAL ELECTRIC COMPANY

  公开号：US20140086846A1

  公开（公告）日：2014-03-27

  A contrast agent composition and a method of diagnostic imaging are provided. The composition comprises a pharmaceutically acceptable carrier and a metal-complex comprising a ligand having structure (XXX): wherein R 1 , R 2 , R 3 , R 7 , R 8 , R′ 1 , R′ 2 , R′ 3 , R 7 ′ and R 8 ′ are selected form hydrogen, a protected C 1 -C 3 hydroxyalkyl group, or a C 1 -C 3 alkyl group; R 4 , R′ 4 are selected from a hydrogen, a hydroxyl, a protected hydroxyl group, a protected C 1 -C 3 hydroxyalkyl group, a C 1 -C 3 alkyl group; n is an integer between 0 and 4; R 5 , R′ 5 are selected from a hydrogen, a protecting group comprising C 1 -C 30 aliphatic radicals, C 3 -C 30 cycloaliphatic radicals, C 2 -C 30 aromatic radicals, m is an integer between 1 and 10; at least one of R 7 and R′ 7 is acidic groups or protected acidic groups; Y comprises a protein or peptide moiety, a particle, a micelle, a liposome, an organic molecule, oligomer, polymer or a hydrophilic moiety.

  提供了一种对比剂组合物和诊断成像方法。该组合物包括一种药用载体和一种金属配合物，其包括具有结构（XXX）的配体：其中R1、R2、R3、R7、R8、R′1、R′2、R′3、R7′和R8′从氢、受保护的C1-C3羟基烷基或C1-C3烷基中选择；R4、R′4从氢、羟基、受保护的羟基烷基、受保护的C1-C3羟基烷基或C1-C3烷基中选择；n是0到4之间的整数；R5、R′5从氢、包含C1-C30脂肪基、C3-C30环烷基、C2-C30芳香基的保护基中选择；m是1到10之间的整数；R7和R′7中至少有一个是酸性基团或受保护的酸性基团；Y包括蛋白质或肽基团、粒子、胶束、脂质体、有机分子、寡聚体、聚合物或亲水基团。
• Hydroxylated phosphorylated contrast enhancement agents
  申请人：General Electric Company

  公开号：EP2552493B1

  公开（公告）日：2015-01-14
• INTERMEDIATES FOR HYDROXYLATED CONTRAST ENHANCEMENT AGENTS
  申请人：Grimmond Brian James

  公开号：US20110077396A1

  公开（公告）日：2011-03-31

  In one aspect, the present invention provides a protected ligand precursor having structure XX wherein R 8 is independently at each occurrence a protected hydroxy group, a protected C 1 -C 3 hydroxyalkyl group, or a C 1 -C 3 alkyl group, and b is 0-4; R 9 -R 11 are independently at each occurrence hydrogen, a protected C 1 -C 3 hydroxyalkyl group, or a C 1 -C 3 alkyl group, with the proviso that at least one of R 8 -R 11 is a protected hydroxy group or a protected C 1 -C 3 hydroxyalkyl group; and R 12 and R 13 are independently at each occurrence a protecting group is selected from the group consisting of C 1 -C 30 aliphatic radicals, C 3 -C 30 cycloaliphatic radicals, and C 2 -C 30 aromatic radicals.
• Hydroxylated Contrast Enhancement Agents
  申请人：Grimmond Brian James

  公开号：US20110076237A1

  公开（公告）日：2011-03-31

  In one aspect, the present invention provides a contrast enhancement agent comprising an iron chelate having structure I wherein R 1 is independently at each occurrence a hydroxy group, a C 1 -C 3 hydroxyalkyl group, or a C 1 -C 3 alkyl group, and b is 0-4; R 2 -R 7 are independently at each occurrence hydrogen, a C 1 -C 3 hydroxyalkyl group, or a C 1 -C 3 alkyl group, with the proviso that at least one of R 1 -R 7 is a hydroxy group or a C 1 -C 3 hydroxyalkyl group; and wherein Q is a charge balancing counterion. Also provided is a metal chelating ligand having structure IX and medical formulations comprising the contrast enhancement I.